New Sjogren's drug enters first human tests
NCT ID NCT07642843
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new injection called CM336 in 30 adults with active Sjogren's syndrome. The main goal is to check safety and how the body handles the drug. Researchers will also look for signs that it helps control the disease. This is a Phase 1 trial, so it's one of the first steps in seeing if the drug might work.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SJÖGREN'S SYNDROME (PSS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.